Zevra Therapeutics (ZVRA) to Release Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) will likely be releasing its earnings data after the market closes on Tuesday, March 11th. Analysts expect Zevra Therapeutics to post earnings of ($0.39) per share and revenue of $8.93 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Zevra Therapeutics Trading Down 8.5 %

Zevra Therapeutics stock opened at $7.33 on Tuesday. The stock has a market cap of $391.25 million, a PE ratio of -3.72 and a beta of 2.00. The stock has a 50-day moving average price of $8.05 and a 200 day moving average price of $8.12. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.76. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZVRA. Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 29th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Guggenheim set a $21.00 price objective on Zevra Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, February 4th. Finally, Canaccord Genuity Group dropped their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zevra Therapeutics presently has a consensus rating of “Buy” and an average target price of $21.71.

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the sale, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. The trade was a 17.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares of the company’s stock, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 85,773 shares of company stock worth $674,176 in the last 90 days. 2.40% of the stock is owned by company insiders.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.